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In part i of this review, the role ofdamage-associated molecular patterns (DAMPs) in mounting inflammation and shaping adaptive 
immunity was briefly described by defining various 
classes of DAMPs that activate and orchestrate several 
innate immune machineries including inflammasomes 
and the unfolded protein response (UPR).1 In brief, 
DAMPs are intracellularly sequestered molecules and 
are hidden from recognition by the immune system 
under normal physiological conditions. However, 
under conditions of cellular stress/tissue injury, 
these molecules can either be actively secreted by 
stressed immune cells; exposed on stressed cells, for 
example, in terms of neo-antigens binding to natural 
immunoglobulin M (IgM) antibodies, or they can be 
passively released into the extracellular environment 
from dying cells or the damaged extracellular matrix.2–6 
DAMPs are recognised by pattern recognition receptor 
(PRR)-bearing cells of the innate immune system, 
including macrophages, leukocytes and dendritic 
cells (DCs) as well as vascular cells, fibroblasts and 
epithelial cells, to promote pro-inflammatory and 
profibrotic pathways.
Various definitions and interpretations of DAMPs 
can be found in the literature and may confuse a new 
reader in this field. Thus, in this article, for didactic 
reasons only and without covering all possible DAMPs, 
they are divided into five partially overlapping classes. 
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abstract: This article is the second part of a review that addresses the role of damage-associated molecular 
patterns (DAMPs) in human diseases by presenting examples of traumatic (systemic inflammatory response 
syndrome), cardiovascular (myocardial infarction), metabolic (type 2 diabetes mellitus), neurodegenerative 
(Alzheimer’s disease), malignant and infectious diseases. Various DAMPs are involved in the pathogenesis of 
all these diseases as they activate innate immune machineries including the unfolded protein response and 
inflammasomes. These subsequently promote sterile autoinflammation accompanied, at least in part, by 
subsequent adaptive autoimmune processes. This review article discusses the future role of DAMPs in routine 
practical medicine by highlighting the possibility of harnessing and deploying DAMPs either as biomarkers for 
the appropriate diagnosis and prognosis of diseases, as therapeutics in the treatment of tumours or as vaccine 
adjuncts for the prophylaxis of infections. In addition, this article examines the potential for developing strategies 
aimed at mitigating DAMPs-mediated hyperinflammatory responses, such as those seen in systemic inflammatory 
response syndrome associated with multiple organ failure.
Keywords: Innate Immunity; Receptors, Pattern Recognition; Inflammation; Adaptive Immunity; Autoimmunity.
امللخ�ض: هذا املقال هو اجلزء الثاين من املراجعة التى تركز على دور االأ�رشار املرتبطة باالأمناط اجلزيئية يف اأمرا�ض الب�رش عن طريق 
عر�ض اأمثلة من الر�سحية )متالزمة ا�ستجابة االلتهاب املجموعي(، القلبية )اأحت�ساء ع�سل القلب(، االأي�سي )النوع الثاين من ال�سكري(، 
)مر�ض الزهامير( و االأمرا�ض اخلبيثة واملعدية. هذه االأمناط املتعددة معنية يف مر�سية جميع هذه االأمرا�ض النها  التنك�ض الع�سبي 
تقوم بتن�سيط اآليات املناعة الطبيعية مبا فيها ك�سف ا�ستجابة الربوتني وااللتهابية. وهذه الحقا تعزز االلتهابات الذاتية املرافقة، على 
االأقل جزئيا عن طريق تالوؤم عمليات املناعة الذاتية. يناق�ض مقال املراجعة هذا م�ستقبل دور االأ�رشار املرتبطة باالأمناط اجلزيئية يف 
والتنبوؤ  املنا�سب  للت�سخي�ض  بيولوجية  اإما كعالمات  االأمناط  ت�سخري ون�رش هذة  امكانية  اإبراز  الروتينية عن طريق  الطبية  املمار�سات 
باالأمرا�ض، اأو عالجية لعالج االأورام اأو كلقاح م�ساعد الإتقاء االلتهابات. اي�سا، يدر�ض هذا املقال جهد تطوير ا�سرتاتيجيات تهدف اإىل 
التخفيف من اآثار جهد فرط االلتهاب امل�ساحب لهذه االإمناط، مثل ماميكن م�ساهدته يف متالزمة ا�ستجابة االلتهاب املجموعي املرتبطة 
مع ف�سل االأع�ساء املتعدد.
مفتاح الكلمات: املناعة الطبيعية؛ امل�ستقبالت، تعرف النمط؛ التهاب؛ مناعة متالئمة؛ مناعة ذاتية.
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In the current article only three classes are covered: 
classes I, II and V. Class I DAMPs are recognised by 
physically binding to PRRs, while class II DAMPs 
are those sensed without directly binding to PRRs. 
Particularly addressed in this article are class V DAMPs, 
or dyshomeostasis-associated molecular patterns (see 
part I).1 Class V DAMPs, in terms of homeostatic 
danger signals, have recently been reported as an 
emerging class of DAMPs in terms of defining an 
altered pattern of molecules reflecting perturbations in 
the steady state of the intracellular and/or extracellular 
microenvironment.3 Such homeostatic DAMPs, when 
associated with endoplasmic reticulum (ER) stress, 
may be sensed by three sensor molecules of the UPR: 
the protein kinase-like eukaryotic initiation factor 2α 
kinase (PERK), the inositol-requiring transmembrane 
kinase/endoribonuclease 1α (IRE1α) and the activating 
transcription factor 6 (ATF6).7–9
The various classes of sterile inflammation-
promoting DAMPs, as true for infectious inflamma- 
tion-evoking pathogen-associated molecular patterns 
(PAMPs), are sensed by a variety of distinct PRRs, 
thereby promoting an inflammatory response. They 
are not reviewed here since PRRs and their triggered 
signalling pathways have recently been the subjects 
of excellent review articles, including those covering 
Toll-like receptors (TLRs),10 receptors for advanced 
glycation end-products (RAGE),11 nucleotide-binding 
oligomerization domain (NOD)-like receptors 
(NLRs),11 C-type lectin receptors (CLRs),12 retonic acid 
inducible gene-I (RIG-I)-like receptors (RLRs)13–15 and 
DNA sensors, including absent in melanoma 2 protein 
(AIM2)-like receptors (ALRs). The recently discovered 
cyclic guanosine monophosphate-adenosine mono-
phosphate (cGAMP) synthase (cGAS) has also been 
covered in recent reviews.15–17  
In part I of this review, the five classes of DAMPs 
were shown to synergistically operate in instigating 
(auto)inflammatory and adaptive (auto)immune 
pathologies as manifested by many human diseases.1 
Two examples of autoimmune diseases, systemic lupus 
erythematosus (SLE) and rheumatoid arthritis, were 
discussed in order to represent a typical paradigm of 
the intimate interplay between innate and adaptive 
immune responses. This second part of the review 
addresses the role of DAMPs in human diseases where 
the involvement of immune processes (in terms of 
adaptive immune processes) were almost unconsidered 
in the past but are now clearly recognised in terms of 
dysregulated innate immune processes.
Traumatic Diseases
The field of trauma impressively reflects the inherently 
ambivalent role of injury-induced DAMPs in medicine 
as their controlled beneficial function instigates the 
whole machinery of inflammation/fibrosis-mediated 
wound healing following any kind of small or moderate 
trauma.18 On the other hand, their uncontrolled 
detrimental action in the case of severe trauma/
polytrauma can lead to the catastrophe of a systemic 
inflammatory response syndrome (SIRS) associated 
with multiple organ failure (MOF).19,20  
Typically, the generation of DAMPs correlates with 
the degree of severity of accidental insults in traumatic 
diseases ranging from small cuts to blunt-force trauma 
and bone fractures or severe large-scale physical 
or thermal injuries.21 Following all these injurious 
lesions, DAMPs, such as high-mobility group box 1 
(HMGB1) and heat shock proteins (HSPs), not only 
induce an acute inflammatory response but are also 
responsible for subsequent tissue repair. Inflammation 
after tissue injury is certainly a critical component 
of wound repair. Innate immune inflammatory cells 
migrate to the wound and promote tissue regeneration 
by removing cellular debris, killing and phagocytosing 
potential invading pathogens, and producing 
cytokines that promote collagen production, cellular 
migration, wound epithelialization and angiogenesis. 
In fact, any post-injury profibrotic and angiogenic 
response, for example after surgery or accidental 
trauma, is mediated by DAMPs-activated PRRs-
expressing innate immune cells such as fibroblasts, 
epithelial cells, macrophages and vascular cells.18,22,23 It 
is the DAMPs and their triggered pathways, together 
with the surrounding cytokine and growth factor 
milieu, that ultimately determine whether or not these 
post-injury innate cellular responses cause mild acute 
inflammation and wound healing,22,24 or subchronicly 
on-going inflammation and fibrosis.25 In very severe 
trauma, when DAMPs are produced in very high 
concentrations and systemically released, they can 
cause acutely occurring SIRs that may be accompanied 
by MOF.25 
In severe trauma in humans, HMGB1 has been 
found to be systemically released within 30–60 minutes, 
peaking two to six hours after injury. Remarkably, 
patients who develop organ dysfunction and non-
survivors of severe trauma have been observed to have 
very high levels of this DAMP. Moreover, HMGB1 
levels were found to be predictive of outcome of 
traumatic lesions as shown, for example, in patients 
with traumatic brain injury.26–28 Moreover, in extensive 
trauma, increasing attention has been devoted to the 
crucial role of mitochondria-derived DAMPs, since 
they have been shown to be markedly elevated in 
severely injured patients.29 This category of DAMPs 
mainly includes circular DNA strands containing 
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C-phosphate-G (CpG) DNA repeats, N-formylated 
peptides and mitochondrial DNA (mtDNA) itself.30 
Interestingly, it has been found that mtDNA, observed 
to directly activate neutrophils after binding to TLR9, 
are released under various traumatic conditions 
including shock and severe traumatic brain injury.31,32 
Recent clinical studies in massively injured human 
subjects provided the first observational evidence 
that plasma mtDNA DAMPs are associated with the 
evolution of SIRS, MOF and mortality.33 One of the most 
interesting reported findings was that a determination 
of mtDNA DAMPs levels made within eight hours of 
hospital admission allowed a differentiation between 
survivors and non-survivors.33
Interestingly, the humoral part of the innate immune 
system, which is likely to be induced by class IV DAMPs 
in terms of injury-induced neo-antigens, namely the 
complement system, is activated immediately after 
trauma as well. In fact, severe, sterile, injury-induced, 
systemic intravascular activation of the complement 
cascade (in particular, the mannose-binding lectin-
mediated pathway) reportedly can promote MOF by 
contributing to a fulminant inflammatory response 
associated with disseminated intravascular coagulation 
and comprised microcirculation.34
Cardiovascular Diseases
Most cardiovascular diseases (CVDs) develop on 
the basis of atherosclerosis. For many years, athero-
sclerosis was simply regarded as a consequence 
of the accumulation of lipids in the vessel walls. 
Today, the picture has completely changed. Current 
notions in vascular biology hold that vessel wall 
injury-induced DAMPs elicit pro-inflammatory, 
profibrotic and adaptive autoimmune responses to 
promote atherogenesis as the underlying disorder of 
CVDs, the most common being coronary artery and 
cerebrovascular diseases.35–37 
Atherosclerosis
A large variety of stressful stimuli and inciting events 
to the arterial wall, including hypertension, diabetes, 
hyperlipidaemia, drugs and chemical toxins, can lead 
to vascular injury associated with the creation of 
various DAMPs. Remarkably, most of these injuries are 
mediated by the generation of reactive oxygen species 
(ROS), a typical example being hypertension, an 
insult-mediating injurious factor that has been already 
described for SLE.1,38 Accordingly, numerous studies 
have identified oxidative stress-induced DAMPs as the 
major activators of innate immune-mediated vascular 
inflammation promoting atherosclerosis.35–37
Low-density lipoprotein (LDL) is a key DAMP 
that accumulates in the subendothelium in the form of 
oxidised LDL (oxLDL) and minimally oxidised LDL. 
Both DAMPs activate vascular cells via recognition 
of their cognate receptors, lectin-like oxLDL receptor 
1 (LOX-1) and TLR4. Further oxidation-specific 
epitopes, for example those derived from oxLDL, 
appear to play a prominent atherogenic role by 
forming a distinct family of DAMPs consisting of 
various categories of oxidative reactions. Other injury-
induced DAMPs, such as HSPs and HMGB1, known 
to bind to TLR2, TLR4 and RAGE on vascular cells, in 
particular on vascular macrophages, are also involved 
in establishing a vascular pro-inflammatory/profibrotic 
cascade contributing to atherogenesis.35–37,39–41 More 
recently, other types of DAMPs released from severely 
damaged cells, such as S100A8/A9, sensed by TLR4 
and RAGE, and mtDNA, sensed by TLR9, have 
increasingly been recognised to contribute to vascular 
innate immunity-mediated inflammatory pathways 
involved in atherogenesis.1,42 
Of note, the NLR-containing pyrin domains 
(NLRP3) inflammasome, located in vascular 
macrophages and smooth muscle cells (SMCs), is 
reportedly also involved in atherogenesis via promotion 
of pro-inflammatory and profibrotic responses. In 
particular, studies on murine and human phagocytes 
and in in vivo settings revealed that crystals of 
cholesterol, operating as DAMPs, activate the NLRP3 
inflammasome required for atherogenesis [Figure 1].36,43
At a later stage of the disease, immunostimulatory 
DCs in the arterial wall, activated after recognition 
of DAMPs through PRRs, engulf and process stress/ 
injury-induced neo-antigens in terms of altered/
modified self-proteins generated in early atherosclerotic 
lesions such as the oxidatively modified apolipoprotein 
B100 component of LDL, HSPs and others. The vascular 
autostimulatory DCs then present these altered 
self-proteins as peptide/major histocompatibility 
complex (MHC) complexes to naïve autoreactive T 
cells in secondary lymphoid tissues of the host, leading 
to an adaptive T cell autoimmune response. In a 
vicious cycle, cytotoxic effector T cells then migrate 
into arterial lesions where they cause further vascular 
injury, leading to the induction of DAMPs that again 
initiate pro-inflammatory and/or profibrotic innate 
immune pathways [Figure 1].35–37
It is of note that homeostatic danger signals, 
denoted here as class V DAMPs, can initiate an 
UPR in endothelial cells (ECs), SMCs and vascular 
macrophages. In fact, multiple local stressors 
in the arterial wall, including to the presence of 
ROS and oxidised lipids, shear stress and increa- 
sed homocysteine-/cholesterol-mediated stress, have 
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been shown to cause ER stress in vessel cells during 
the initiation and progression of atherosclerosis. As 
highlighted in a recent review, the activation of the 
various UPR signalling pathways displays a temporal 
pattern of activation at different stages of the disease.44 
Thus, the ATF6 and IRE1α pathways are activated 
in ECs in athero-susceptible regions of pre-lesional 
arteries whereas the PERK pathway is activated in 
SMCs and macrophages in early lesions.1 With the 
progression of atherosclerosis, the extended duration 
and increased intensity of ER stress in lesions lead 
to prolonged and enhanced UPR signalling. Under 
this circumstance, the PERK pathway induces the 
expression of death effectors and, possibly, IRE1α 
activates apoptosis signalling pathways. This leads 
to the apoptosis of macrophages, ECs and SMCs 
in advanced lesions. The subsequent unavoidable 
elicitation of other classes of DAMPs, then, may 
promote what is now UPR-independent vascular 
inflammation. It is likely this occurs in terms of a 
crosstalk with the NLRP3 inflammasomes located 
in macrophages, thereby contributing to the clinical 
progression of atherosclerosis.45
Myocardial Infarction
In regard to CVDs, a myocardial infarction (MI) is 
a classic example of an atherosclerosis-associated 
acute disease. Its pathophysiology is a typical 
example of consequences in the course of ischaemia 
plus postischaemic reperfusion injury (IRI), here to 
the myocardium mediated by a burst of ROS—in 
particular, mitochondria-derived ROS.46,47 Notably, 
experimental data suggest that up to 50% of the final 
infarct size may be related to IRI.48 Again, DAMPs are 
predominantly involved in this pathogenetic scenario.49 
Induced by IRI and subsequently recognised by PRR-
bearing cells (for example, neutrophils), DAMPs elicit 
a sterile inflammatory response following primary 
coronary artery occlusion. Thus, DAMPs such as 
HMGB1, adenosine triphosphate (ATP) and S100A8/
A9 have been shown to be locally released following 
a MI. Recognition of these DAMPs by PRRs such as 
TLRs (e.g. TLR3 and TLR4) trigger innate immune 
pathways to evoke an inflammatory response that 
aggravates the primary IRI to the myocardium.42,50–53 
Of note, activation of the NLRP3 inflammasome by 
DAMPs, such as ATP, plays an eminent role in the 
creation of a myocardial inflammatory response that, 
as stressed above, increases the infarction size.53–55  
Moreover, the patient’s long-term outcome after a 
MI event is influenced by innate immune responses 
as well. Thus, post-MI, a controlled inflammatory/
fibrotic innate immune response can lead to the 
clearance of injured tissue, angiogenesis and the 
proliferation of fibroblasts, eventually resulting in scar 
Figure 1: Scenario model of vascular DAMPs-induced innate and adaptive immune responses involved in atherogenesis.
DAMPs = damage-associated molecular patterns; neoAg = neo-antigens (altered-self antigens); oxLDL = oxidised low-density lipoprotein; 
HSP60 = heat shock protein 60; Th1 = T helper 1 subset of CD4+ cells; TH17 = T helper 17 subset of CD4+ cells; PRRs = pattern recognition 
receptors; IL-1R = interleukin-1 receptor; NLRP3 = nucleotide-binding oligomerization domain (NOD)-like receptor-containing pyrin domain 
3; NF-κB = nuclear factor kappa B; MAPKs = mitogen-activated protein kinases; proIL-1β = prointerleukin-1-beta; IL-1β = interleukin-1-beta; 
TGF-β = transforming growth factor-beta; DC = dendritic cell; MØ = macrophage; VSMC = vascular smooth muscle cell; UCM = upregulation 
of costimulatory molecules; MHC = major histocompatibility complex; ECM = extracellular matrix; TCR = T cell receptor.  
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formation and infarct healing. However, uncontrolled 
dysregulation of the response, as shown in mice, and 
under involvement of the NLRP3 inflammasome may 
result in DAMPs-driven continued cardiomyocyte 
loss. This results in the overshooting of fibrosis beyond 
the limits of the infarcted area, reactive hypertrophy 
and chamber dilatation. This process is termed adverse 
cardiac remodelling and is known to lead to functional 
compromise and heart failure.54,56 
Metabolic Diseases
In the case of metabolic diseases, class V DAMPs 
play a crucial role. As mentioned above, this class of 
DAMPs can be generated by intracellular stress in non-
dying cells. This can occur by the slightest metabolic 
perturbations of the homeostasis within the intra/
extracellular microenvironment. Such a scenario can 
be observed in diseases such as type 2 diabetes (T2D) 
and metabolic syndrome. Additionally, in obesity, as in 
T2D, primary perturbations of the ER provoke a chain 
of different classes of DAMPs that, via recognition 
by PRR-bearing cells, promote innate immune tissue 
inflammation resulting in cell/organ dysfunction. That 
metabolism and innate immunity are linked is perhaps 
not surprising as both systems involve recognition of 
exogenous stressors. But proper handling, in general, 
leads to the maintenance of homeostasis. In fact, 
recent studies have revealed intriguing molecular 
associations between these two processes which 
could give rise to substantial new insights into the 
pathogenesis of inflammatory diseases, as briefly 
described below using the example of T2D.57
T2D represents a prototypical innate immune 
disease where DAMPs-induced, PRR-triggered sterile 
autoinflammatory processes lead to β cell dysfunction 
and ultimately cell death (pyroptosis).58–61 Current 
notions hold that metabolic insults such as insulin 
resistance, prolonged hyperglycaemia and increased 
free fatty acid levels (mechanistically explained 
by depleting ER calcium levels) leads to excessive 
stimulation of insulin production in the β cells that are 
associated with protein (proinsulin) accumulation in 
the ER.1
The increasing protein (proinsulin) overload, 
however, leads to a disruption of ER homeostasis 
which results in the accumulation of newly synthesised 
unfolded/misfolded proteins in the ER lumen, which 
can be regarded as class V DAMPs.62–64 This scenario 
elicits a metabolic perturbation of the ER, which 
becomes exhausted, thereby causing ER stress that is 
usually associated with oxidative stress.65,66 As noted in 
part one of this review, this kind of ER stress/oxidative 
stress activates signalling pathways of the UPR 
whereby the three branches of the UPR—PERK, IRE1α 
and ATF6—sense those accumulating misfolded 
proteins via their function as recognition receptors.1 
Consequently, it is the prolonged or excessive function 
of the β cell UPR that provokes a local inflammatory 
response in terms of a crosstalk with other members 
of the innate immune system that, via aggravation of 
insulitis, finally contributes to β cell dysfunction and 
death in T2D.1,59,63,67
At this point, class I and II DAMPs come into play 
by activating, in islet cells and resident islet 
macrophages, the NLRP3 inflammasome as well 
as other NLRP3-related and NLRP6-dependent 
pathways.60,61,68–73 The priming step of NLRP3 
inflammasome activation is reportedly believed to 
be instigated by systemic and/or islet tissue-derived 
class I DAMPs, including HMGB1, HSP70, fatty acids 
(palmitate) and islet amyloid polypeptide; the last of 
these is also discussed as an NLRP3 activator. These 
DAMPs can stimulate TLR2 and TLR4 expressed 
in islets and pancreatic macrophages to trigger 
transcriptional pathways, leading to the activation 
of nuclear factor kappa β (NF-kβ) and mitogen-
activated protein kinases (MAPKs).59–61,72,74,75 Of 
note, for the first time, UPR-derived class II DAMPs, 
namely thioredoxin-interacting protein (TXNIP), 
have been found to initiate the post-translational 
activation step of the NLRP3 inflammasome in T2D. 
In fact, recent evidence suggests that TXNIP is a 
critical link between ER stress, NLRP3 inflammasome 
activation, islet inflammation and programmed β cell 
death. In the course of hyperactivation of the UPR 
to irremediable ER stress, TXNIP becomes rapidly 
activated by ER stressors via induction by the PERK 
and IRE1α pathway to trigger interleukin(IL)-1β (IL-
1β) production, thereby contributing to local sterile 
islet inflammation [Figure 2].64,75,76
Of note, as also discussed elsewhere, intersection 
and crosstalk between the two tools of the innate 
immune system, the ER stress/UPR-signalling and 
the inflammasome machinery, appear to regulate the 
quality, intensity and duration of innate immune pro-
inflammatory and proapoptotic responses.77,78 This 
reflects a new quality of DAMPs’ role in terms of a 
‘DAMPs axis’—the consecutively operating ‘DAMPs 
axis’ composed of class V DAMPs (misfolded proteins 
in the ER) → class I DAMPs (for example, HSPs) 
→ class II DAMPs (TXNIP) which leads to islet 
inflammation in T2D and contributes to β cell failure. 
Clearly, future studies are needed to determine if the 
proposal of such a ‘DAMPs axis’ reflects an innate 
immune pathway that, in principle, contributes to the 
pathogenesis of metabolic inflammatory diseases or 
even neurodegenerative diseases.
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Neurodegenerative Diseases
The phenomenon of ER stress in association with 
inflammasome-mediated inflammation is also 
encountered in neurodegenerative diseases such 
as Alzheimer’s disease (AD), Parkinson’s disease, 
Huntington’s disease, amyotrophic lateral sclerosis 
and prion-related diseases. All of these have diverse 
clinical manifestations but all involve, besides 
neuroinflammation, the scenario of a ‘perturbed 
proteostasis’, or the accumulation of misfolded 
pathological proteins. Notably, this fact has led to 
their classification as protein misfolding disorders.79 
For example, the hallmark lesions in the pathology 
of AD, which are extracellular deposits of amyloid β 
(Aβ) peptides derived from cleavage of the amyloid 
precursor protein (APP) as well as neurofibrillary 
tangles composed of the hyperphosphorylated Tau 
protein, both arise from protein misfolding in the form 
of oligomers.80  
On the other hand, neuroinflammatory processes 
characterised by the activation of astrocytes and 
microglia and the release of pro-inflammatory mediator 
substances are also recognised as aetiologic events in 
AD evolution. In fact, AD represents a prototypical 
neurodegenerative disease where DAMP-induced 
PRR-triggered sterile autoinflammatory processes 
are associated with neuronal cell dysfunction finally 
leading to neuron death (apoptosis/pyroptosis). 
To date, there are several competing hypotheses that 
attempt to explain which comes first, and what drives 
what in governing AD pathogenesis, including the Aβ 
cascade, Tau protein, oxidative stress and inflammation 
hypotheses.81 However, according to the danger/injury 
model, any stress activates the innate immune system 
which then reacts with an inflammatory response. 
Thus, in the current review article, oxidative stress due 
to the overproduction of ROS caused by a genetically 
determined age-dependent decline in mitochondrial 
function is here proposed to be the ‘head of the snake’ 
of the AD-typical pathologic cascade, phrased here as 
the ‘mitochondrial cascade hypothesis’. 
In fact, increasing evidence suggests that dysfunc-
tioning mitochondria mutually cause oxidative stress 
that is associated with the production of accumulating 
APP-derived Aβ peptide and hyperphosphorylated 
Tau proteins.81 In addition, it is the intraneuronal 
overload of these proteins that, as similarly discussed 
in T2D, leads to ER stress. In fact, ER stress with 
a subsequent UPR may also play a direct role in 
the aetiopathogenesis of sporadic AD.82–84 Thus, 
intraneuronal ER stress in AD is well documented and 
is proposed to be primarily caused by mitochondrial 
dysfunction-mediated production of ROS leading 
to the accumulation of Aβ and Tau proteins. A 
reverse causality is also hypothesised as ER stress is 
primarily caused by accumulating Aβ, subsequently 
promoting oxidative stress [Figure 3].81,85–88 Further, 
Figure 2: Simplified illustration of a scenario modelling the role of DAMPs in UPR-mediated and NLRP3 inflammasome-
promoted islet inflammation and programmed β cell death in type 2 diabetes mellitus. 
DAMPs = damage-associated molecular pattern molecules; UPR = unfolded protein response; NLRP3 = (NOD)-like receptor (NLR)-containing 
pyrin domain 3; HMGB1 = high-mobility group box 1; ER = endoplasmic reticulum; ROS = reactive oxygen species; IAPP = islet amyloid 
polypeptide; TLR = Toll-like receptor; PERK = protein kinase-like eukaryotic initiation factor 2α kinase; IRE1α = inositol-requiring 
transmembrane kinase/endoribonuclease 1α; TXNIP = thioredoxin-interacting protein; pro-IL-1β = pro-interleukin-1β; NF-κβ = nuclear factor 
kappa β; MPKs = mitogen-activated protein kinases; IL-1β = interleukin-1β; IL-1R = interleukin 1 receptor.
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as has been discussed elsewhere, the additional 
promotion of ER stress in AD is provided by on-
going chronic mitochondrial dysfunction, resulting in 
continuously greater oxidative stress associated with 
accumulating Aβ oligomers, as well as contributing 
to calcium dyshomeostasis and DNA alterations 
in the form of oxidised mtDNA.83,87,89,90 Finally, all 
of these intraneuronally accumulating molecules 
induce permanent ER stress, promoting an UPR 
which reportedly has been activated in postmortem 
brain samples from AD patients.82–84,91,92 In other 
words, these ER stress-inducing molecules operate 
as class V DAMPs that are recognised by the three 
stress sensors: PERK, IRE1 and ATF6. This promotes 
the UPR signalling network. Interestingly, a growing 
body of evidence suggests that DAMPs-induced UPR 
signalling events may actually control the expression 
of diverse AD-related proteins as well as early steps of 
APP maturation and processing.82,83  
Again, as has been similarly proposed for T2D, a 
DAMPs-driven innate immune crosstalk between ER-
stress/UPR and NLRP3 activation can be discussed 
for AD that may contribute to pro-inflammatory and 
proapoptotic responses, as pathognomonically observed 
in AD. According to current notions, however, this 
crosstalk does not take place in a single cell but between 
two cell types: neurons (ER stress-UPR) and microglia/
astrocytes (NLRP3 inflammasome) [Figure 3].
In fact, inflammasome-dependent pathways 
appear to play an emerging role in the pathogenesis 
of neuroinflammation, including AD.93 In particular, 
the NLRP3 inflammasome has recently gained 
increasing attention.94 In vivo studies, cell experiments 
and investigations on transgenic APP/PS1 mice 
have shown that fibrillar Aβ, obviously acting as a 
class II DAMP, activates the NLRP3 inflammasome 
to produce microglial IL-1β. Phagocytosis of Aβ 
and subsequent lysosomal damage associated 
with the release of cathepsin B were identified to 
initiate NLRP3 inflammasome activation promoting 
neuroinflammation.1,95,96 It is conceivable that 
stress- or apoptosis-derived class I DAMPs may 
promote priming of the NLRP3 inflammasome as 
transcriptionally triggered by TLRs. Thus, class I 
DAMPs, such as neuronal stress-induced HSP72 as 
well as TLRs of the microglia including TLR2, 4 and 
9, have been discussed and reported to be involved 
in AD-associated neuroinflammation.80,97–100 In turn, 
microglial NLRP3 inflammasome products, such as 
IL-1β, promote AD pathology via contributions to 
intraneuronal amyloidogenesis and the formation 
of neurofibrillary tangles. This results in an innate 
vicious immune circle of pathogenic pathways in AD 
[Figure 3].93,94,96,101
Taken all together, a wealth of information has 
recently emerged that links ER stress/UPR and 
Figure 3: Simplified illustration of a scenario modelling the role of DAMPs in ER stress/UPR-mediated, NLRP3-promoted 
neuroinflammation and neuronal cell death in Alzheimer’s disease.
ER = endoplasmic reticulum; UPR = unfolded protein response; NLRP3 = nucleotide binding oligomerization domain (NOD)-like receptor 
(NLR)-containing pyrin domain 3; ROS = reactive oxygen species; IL-1β = interleukin-1β; Aβ = amyloid β; TAU = Tau protein; Ca2+ = calcium 
ion; PERK = protein kinase-like eukaryotic initiation factor 2-alpha kinase; IRE1α = inositol-requiring transmembrane kinase/endoribonuclease 
1α; ATF6 = activating transcription factor 6; proIL-1β = prointerleukin-1β; TLRs = Toll-like receptors; HMGB1 = high-mobility group box 1; HSPs 
= heat shock proteins.
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NLRP3 inflammasome signalling to AD pathogenesis. 
However, the precise roles of these innate immune 
pathways in promoting and modulating AD remain 
elusive. Still, AD must be regarded as a complex 
neurodegenerative disease with an unclear aetiology.
Malignant Diseases: 
Anticancer therapy
The role of DAMPs in malignant diseases is a 
therapeutic one—to attempt to eradicate tumours 
via the elicitation of DAMPs. Notably, the field 
of anticancer therapy has recently experienced a 
significant paradigm shift. An expanding body of 
evidence now indicates that antineoplastic agents 
do not mediate their therapeutic effects due to their 
capacity to directly kill malignant cells but rather 
actively stimulate adaptive anti-tumour immune 
responses via the induction of DAMPs.
In general, apoptotic cell death, as characterised 
by a morphologically homogenous entity, has been 
considered essentially non-immunogenic—that is, 
intrinsically tolerogenic. Thus, cancer cells undergoing 
a kind of physiological apoptosis cause an induction 
of tolerance towards cancer antigens. The already 
low immunogenic cancer cells are further cleared up 
‘silently’ by phagocytes without evoking inflammation 
and anti-tumour immunity, a phenomenon called 
tolerogenic cell death.
However, growing evidence indicates that certain 
chemotherapeutics, radiotherapy and photodynamic 
therapy can induce a functionally distinct type of 
apoptosis in cancer cells that is associated with the 
generation of immunogenicity-promoting DAMPs. 
Notably, these DAMPs assist in initiating an adaptive 
anti-tumour immune response, which is a phenomenon 
called immunogenic cell death (ICD) induced by ICD 
inducers.102–104 Of note, it is the spatiotemporally-
defined generation of those DAMPs—the pre-, early-, 
mid- or late apoptotic emission of DAMPs—that are 
sensed by PRR-bearing cells of the innate immune 
system, thereby keeping the immune system alert in 
a pro-inflammatory state.102,105 Key DAMPs generated, 
trafficked and emitted by dying cancer cells that are 
found to be crucial for cancer immunogenicity include 
ER-derived calreticulin (CRT) and HSP70 exposed 
at the cell surface. Additionally, ATP extracellularly 
secreted in a complex mechanistic manner, nucleic 
acids and HMGB1 in a special redox modification are 
released from dying cells. 103,105–107 For example, during 
ICD, secreted extracellular ATP (eATP) mainly binds 
the P2X purinoceptor 7 receptors causing activation 
of the NLRP3 inflammasome which in turn leads 
to caspase-1-mediated processing and secretion of 
active IL-1β.1,108  
Interestingly, the phenomenon described above 
is also at work in all scenarios of ICD; emerging 
molecular links between ROS-based ER stress, UPR 
signalling, DAMPs and anti-tumour immunity have 
recently been revealed.102,105 In fact, the efficient 
emission of DAMPs from dying cancer cells relies 
on the joint induction of ROS and ER stress, 
which governs the trafficking of those DAMPs. For 
example, chemotherapy-induced pre-apoptotic CRT 
translocation to the cell surface has been found to 
be mediated by co-interaction with PERK-induced 
eukaryotic initiation factor 2α phosphorylation, ER-to-
Golgi transport and the classical secretory pathway.1 
Similarly, the pre-apoptotic secretion of the class 
II DAMP eATP is mediated by secretory pathways 
including the classical and PERK-regulated proximal 
secretory pathway [Figure 4].1,97,106,109,110 Hence, a 
robust ER stress response, preferably accompanied by 
or induced by ROS production, is a salient biochemical 
prerequisite for the generation of homeostatic danger 
signals/class V DAMPs that are sensed by branches of 
the UPR, thereby activating the UPR in the scenario of 
ICD. In other words, the induction of as-yet-unknown 
class V DAMPs, via a complex interplay between 
ER stress and ROS production, initiate signalling 
pathways to emit secondary class I and II DAMPs 
such as pre-apoptotic CRT, early apoptotic eATP, 
and mid/late apoptotic HMGB1 and HSPs, leading 
to an ICD-induced adaptive anti-tumour immune 
response [Figure 4].
In fact, these class I and II DAMPs in the company 
of cancer cell antigens cause maturation of DCs, 
which ultimately activate an anti-tumour cluster 
of differentiation (CD) 4+/CD8+ T cell immune 
response.1,105 Indeed, it currently appears that the 
immunogenic characteristics of dying cells (in the form 
of apoptotic, autophagic, necroptotic and pyroptotic 
cell death) are mainly mediated by DAMPs. The 
DAMPs, via induction of immunostimulatory tumour 
antigen-presenting DCs, elicit pathways leading to the 
development of an innate/adaptive immune defense 
response against tumours. This occurs following 
ICD induction, thereby contributing to the immune-
mediated eradication of tumours.102,105,111 
Infectious Diseases
The dominating role of DAMPs in human diseases 
is strikingly, but perhaps unexpectedly, reflected by 
their participation in infectious disorders. In fact, their 
inflammation-amplifying effect in infectious diseases 
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is already well known. However, there is growing 
evidence in support of the notion that DAMPs are the 
real players in instigating and mounting a vigorous 
injurious inflammatory response against invading 
pathogens, resulting in an adaptive anti-pathogen 
immune response.112–115 In particular, overwhelming 
evidence in support of this theory has come from 
recent insights into the function of the mammalian 
gut’s innate immune system’s ability to discriminate, 
under the control of DCs and regulated by innate 
immune PRRs, between harmless commensal bacteria 
to induce immune tolerance and harmful pathogenic 
bacteria to induce inflammation and immunity.112–115 
In other words, commensals, although possessing 
PAMPs, do not cause inflammation and adaptive 
immunity. This is a notion that has led to the creation of 
the more precise term, microbe-associated molecular 
patterns (MAMPs), given the fact that the microbial 
ligands sensed by PRRs are not necessarily confined to 
pathogens, but are also present in commensal bacteria. 
In fact, on a molecular level, it appears unlikely that 
the innate immune system possesses the ability to 
distinctly discriminate between the myriads of non-
pathogenic commensals within the gut microbiota and 
those that operate as injuring pathogenic microbes. 
Rather, this function may be achieved by recognising 
pathogen-induced DAMPs in addition to MAMPs, 
which do not emit a danger signal per se, that is, by 
sensing altered patterns of molecules associated with 
cell/tissue damage caused by pathogenic microbes 
[Figure 5]. In the following section, a few examples of 
the role of DAMPs in cooperation with MAMPs in 
pathogen-induced infectious inflammation are briefly 
touched upon.
As mentioned above, any perturbation of physical 
or homeostatic conditions within the cell reflects the 
presence of class V DAMPs. This seems also to be true 
for cell stress as provoked by viral or bacterial infection, 
as has been discussed elsewhere.116 For example, 
virus entry requires membrane and cytoskeletal 
perturbation/disruption, and both membrane fusion or 
actin-depolymerising agents alone are able to activate 
antiviral genes. Accordingly, recent studies using 
virus-like particles have supported this hypothesis.117 
In addition, viruses cause cellular stress and change 
the cellular environment. In particular, viruses 
provoke oxidative stress or ER stress accompanied 
with oxidative stress, thereby inducing ‘homeostatic’ 
class V DAMPs. Even simpler, both viruses and 
intracellular bacteria cause cell stress through their 
replication alone. Broad changes to the cellular 
environment, including host translational inhibition 
and overexpression of viral proteins could cause ER 
stress associated with the generation of DAMPs. 
Collectively, these DAMPs-induced pathways lead 
to ampification of PRR-triggered antiviral signalling, 
converging, for example, on the activation of the 
transcription factor interferon regulatory factor 3.85,116
Figure 4: Simplified diagram of a schematic illustration of the role of DAMPs in the elicitation of adaptive anti-tumour 
immune responses. Compare also Figure 4 in part 1 of this review.1
DAMPs = damage-associated molecular patterns; ICD = immunogenic cell death; ROS = reactive oxygen species; ER = endoplasmic reticulum; 
CRT = calreticulin; HMGB1 = high-mobility group box 1; HSPs = heat shock proteins; PERK = protein kinase-like eukaryotic initiation factor 2α 
kinase; UPR = unfolded protein response; eATP = extracellular adenosine triphosphate; mDC = mature dendritic cell.
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In addition to ER stress-provoked class V DAMPs, 
class I and II DAMPs can be exposed or released 
from bacteria- or virus-infected cells. Thus, in studies 
on mice, the DAMP, S100A9, was identified as an 
activator of TLR signalling during influenza A virus 
(IAV) infection.118 S100A9 was found to be released 
from undamaged IAV-infected cells and extracellular 
S100A9 acted as a critical host-derived molecular 
pattern to regulate inflammatory response outcomes 
and disease during infection by exaggerating the 
pro-inflammatory response, cell death and virus 
pathogenesis. Furthermore, the inflammatory activity 
of extracellular S100A9 was mediated by activation of 
the TLR4-MyD88 pathway.118  
In accordance with these observations in mice are 
studies on a bacterial high-grade sepsis model in non-
human primates that allowed quantification of DAMPs 
and PAMPs after bacterial challenges of increasing 
clinical severity.119 These studies allowed a definition for 
the contribution of bacterial PAMPs and endogenous 
DAMPs to clinical organ dysfunction in septic and 
sterile SIRS.119 Interestingly, the experiments showed 
that the degree of clinical severity of the bacterial 
sepsis reflecting the tissue/organ injury correlated 
with the concentration of the circulating mtDNA 
DAMP better than with bacterial DNA acting as a 
PAMP. This indicates that DAMPs from septic injury, 
rather than PAMPs, determine the clinical course 
of bacterial sepsis. In particular, the study showed 
that following a lethal bacterial challenge, bacterial 
DNA only transiently increased while mtDNA levels 
remained elevated until death, suggesting on-going 
tissue damage long after the bacteria were cleared. 
It is of note that the clinical relevance of the role of 
DAMPs, as assessed by findings from this non-human 
primate sepsis model, has been stressed by a recently 
performed clinical study showing that the mtDNA 
DAMP was elevated in the blood of patients suffering 
from severe sepsis.120
Outlook
Without a doubt, DAMPs will have a considerate 
impact on routine practical medicine in the future. 
They could be used as either biomarkers for the proper 
diagnosis and prognosis of diseases, or as therapeutics 
in the treatment of tumours or in vaccines for 
prophylaxis of infections. The use of DAMPs as 
biomarkers is indeed emerging; thus, in view of the 
possibility of three different types of injury-induced 
innate immune responses, clinicians are eager to know 
at an early stage what pathogenic pathways will be 
induced by a given injury in a patient.Will the injury 
have a controlled response, leading to smooth wound 
healing and scar formation? Will the injury undergo 
symptomless infarct healing after a MI? Or will the 
injury result in a catastrophically uncontrolled acute 
hyperinflammatory/chronic overshooting repara- 
tive response? Will SIRS follow polytrauma or 
cardiac dilative remodelling after a MI, leading to 
Figure 5: This model shows commensal microbes expressing MAMPs which are protected by immunotolerance. 
Pathogenic microbes, expressing MAMPs and causing injury-induced DAMPs, are eliminated by inflammation and 
immunity.




functional compromise and heart failure? Indeed, the 
measurement of DAMPs in terms of biomarkers in 
such situations will be helpful in assessing the degree 
of the underlying lesions, ensuring the right diagnosis, 
making personalised DAMPs-based therapeutic 
decisions and assigning valid outcome prognoses. 
For example, interfering with DAMPs-induced innate 
immune pathways such as NLRP3-mediated pathways 
may be a good treatment option to prevent SIRS or 
dilative cardiac remodelling.
In addition, the induction of DAMPs by special 
treatment modalities to eradicate tumours is also 
emerging. In fact, the new insights into the role of 
DAMPs in successfully eliciting anti-tumour immune 
responses have opened modern perspectives for the 
development of treatment modalities aiming to cure 
cancer. Accordingly, it would be desirable to identify 
class V DAMPs evoked by ER stress or other processes 
such as autophagy that instigate UPR signalling in 
cancer cells leading to exposure and/or secretion of 
class I and II DAMPs, thereby eliciting adaptive anti-
tumour T cell immunity.
In contrast to such treatment of tumours, namely 
to promote ER stress-associated class V DAMP 
formation to instigate an UPR, future treatment 
strategies in metabolic and neurodegenerative 
diseases should include efforts to interfere with the 
ER stress-associated generation of dyshomeostatic 
class V DAMPs. In regard to elucidating mechanisms 
involved in both pathways, future research will have 
to concentrate on efforts to explore the precise 
mechanism involved in the network of ER stress ↔ 
generation of class V DAMPs → UPR signalling ↔ 
induction of class I and II DAMPs.
Finally, with respect to the detrimental role of 
DAMPs in amplifying infectious or sterile injury-induced 
inflammation, another attractive therapeutic modality 
emerges at the horizon—to develop strategies which 
specifically inhibit or at least mitigate DAMPs-mediated 
hyperinflammatory responses without compro- 
mising the anti-pathogen innate/adaptive immune 
response. In fact, such a possibility may help to improve 
the clinical management of infection- or injury-evoked 
hyperinflammatory diseases such as SIRS.
Conclusion
This article is part II of a review addressing the role 
of DAMPs in human diseases, focusing on traumatic, 
cardiovascular, metabolic, neurodegenerative, malig-
nant and infectious diseases. Available research in 
this area shows that there is certainly a future role for 
DAMPs in routine practical medicine as they could be 
used as either biomarkers for the proper diagnosis and 
prognosis of diseases, as therapeutics in the treatment 
of tumours or in vaccines for prophylaxis of infections. 
Using DAMPs as biomarkers would be advantageous 
in assessing the degree of underlying lesions, ensuring 
the right diagnosis and assigning valid outcome 
prognoses. In addition, the ‘dampening’ of DAMPs 
could also help to improve the clinical management 
of infection- or injury-evoked hyperinflammatory 
diseases such as SIRS. Research has also shown 
there is a plausible role for DAMPs in eliciting anti-
tumour immune responses, which could lead to 
groundbreaking developments in treatment modalities 
aiming to cure cancer.
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